. 2018 May 21;46(3):539–547. doi: 10.1007/s00068-018-0961-4

Table 5.

Outcome for the matched pairs separated by treatment (N = 40)

	Non-operative treatment (N = 20)	Operative treatment (N = 20)	P value
HLOS (days)^a	23 (17–42)	21 (12–33)	0.028^c
Primary IC admission^b	19 (95%)	19 (95%)	1.000^d
Primary ICLOS (days)^a	12 (3–29)	5 (3–13)	0.131^c
IC readmission^b	0 (0%)	1 (5%)	1.000^d
Secondary ICLOS (days)^a	17 (17–17)	7 (N.D.)	N.A
Cumulative ICLOS (days)^a	12 (3–29)	5 (3–13)	0.172^c
Primary mechanical ventilation^b	11 (55%)	17 (85%)	0.070^d
Primary mechanical ventilation (days)^a,e	17 (9–22)	4 (2–10)	0.021^c
Re-intubation^b	2 (80%)	0 (0%)	NA
Secondary mechanical ventilation (days)^a	25 (N.D.)	ND	NA
Cumulative mechanical ventilation (days)^a	18 (12–26)	4 (2–10)	0.012^c
Chest tube (N patients)^a	15 (75%)	20 (100%)	0.063^d
Chest tube (days)^a,f	9 (5–9)	6 (5–9)	0.282^c
Adverse event^b	18 (90%)	11 (55%)	0.065^d
Surgery-related adverse events
Surgical site infection	NA	2 (10%)	NA
Crosslinking ribs	NA	1 (5%)	NA
Splint through cortex	NA	1 (5%)	NA
Bleeding	NA	2 (10%)	NA
General adverse events
Pneumonia	16 (80%)	7 (35%)	0.035^d
Respiratory insufficiency	0 (0%)	1 (5%)	1.000^d
Empyema	0 (0%)	0 (0%)	NA
Delirium	7 (35%)	3 (15%)	0.289^d
Overall in-hospital mortality^b	1 (5%)	2 (10%)	1.000^d
Injury-related in-hospital mortality^b	0 (0%)	1 (50%)	1.000^d

Data are presented as ^amedian (P₂₅–P₇₅) or as ^bnumber (%) and were analyzed with a ^cWilcoxon signed ranks test or a ^dMcNemar test. Boldface fonts indicate statistically significant differences

Data missing for ^etwo, ^fthree

CLOS intensive care length of stay, HLOS hospital length of stay, NA not applicable